Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Glenmark Pharmaceuticals Revenue

In the fiscal year ending March 31, 2026, Glenmark Pharmaceuticals had annual revenue of 174.43B INR with 30.53% growth. Glenmark Pharmaceuticals had revenue of 39.60B in the quarter ending March 31, 2026, with 20.07% growth.

• Revenue: 174.43B
• Revenue Growth: +30.53%
• P/S Ratio: 3.68
• Revenue / Employee: 11.04M
• Employees: 15,800
• Market Cap: 641.98B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Mar 31, 2026	174.43B	40.80B	30.53%
Mar 31, 2025	133.63B	7.18B	5.68%
Mar 31, 2024	126.45B	9.90B	8.49%
Mar 31, 2023	116.56B	-6.49B	-5.28%
Mar 31, 2022	123.05B	13.61B	12.44%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 1, 2026

Data Sources Report a data error